Akkermansia Muciniphila: The Gut Bacterium That Predicts Longevity (2026)

One gut bacterium shows up consistently in the profiles of centenarians, metabolically healthy adults, and high-performers optimizing for longevity. It lives in the mucus layer coating your intestinal wall, feeds on that mucus, and paradoxically triggers your gut to produce more mucus – thickening the barrier that prevents bacterial lipopolysaccharides (LPS – inflammatory molecules from gram-negative bacteria) from leaking into your bloodstream.

Its name is Akkermansia muciniphila.

For years it was a scientific curiosity – a species identified in 2004 but rarely mentioned outside microbiology labs. Then in 2017, Patrice Cani's team at UCLouvain (Catholic University of Louvain, Belgium) published a study showing that a pasteurized form of this bacterium reversed metabolic disease in mice and improved glucose control in humans. A company called Pendulum Bioscience built a probiotic around it. Halle Berry invested and became Chief Communications Officer. The product now costs $65–75 per month, or roughly $780–900 per year.

The question: Is this the bacterial equivalent of taking NMN – a scientifically-grounded intervention that moves the needle on longevity markers? Or is it a well-funded wellness product riding the hype of a single species? The answer is genuinely complicated.

This guide covers the full evidence – what Akkermansia does, why centenarians have more of it, the live vs. pasteurized tension that hasn't been resolved in humans, how to boost it naturally for free, and an honest assessment of whether a supplement makes sense for you.

TL;DR

• Akkermansia muciniphila is a gut bacterium enriched in centenarians, metabolically healthy adults, and those with lower body fat and better insulin sensitivity
• It lives in the mucus layer, produces compounds that strengthen the gut barrier, trigger GLP-1 secretion (the hormone behind satiety and glucose control), and reduce systemic inflammation via TLR2 activation
• The landmark Plovier 2017 study showed pasteurized Akkermansia was more effective than the live form — yet most commercial probiotics use live bacteria and market colonization
• Only one human RCT tested a multi-strain probiotic containing Akkermansia (Perraudeau 2020, n=76) — it showed -0.6% HbA1c and -33% postprandial glucose area-under-curve in type 2 diabetes, but hasn't been independently replicated
• Natural ways to boost Akkermansia (polyphenols, metformin, intermittent fasting, exercise) have stronger evidence bases than any probiotic supplement
• Safety concern: Akkermansia-specific IgG appears in cerebrospinal fluid of MS patients; context-dependent worsening of autoimmune disease in some microbiome profiles; very high Akkermansia (>4.66% of microbiota) correlates with worse cancer immunotherapy outcomes
• Who might benefit: type 2 diabetics on metformin (additive effect), individuals with documented low Akkermansia, those recovering from antibiotics
• Bottom line: The science is real, but the supplement evidence is thin; natural boosters (polyphenols, fasting, metformin) should come first

What is Akkermansia Muciniphila? The Discovery

Akkermansia muciniphila was first formally characterized in 2004 by Muriel Derrien, Elaine Vaughan, Caroline Plugge, and Willem de Vos at Wageningen University in the Netherlands (PMID 15388697, International Journal of Systematic and Evolutionary Microbiology). Its name reflects its habitat: "Akkermansia" honors the lab, "muciniphila" means "mucus-loving." It colonizes the mucus layer of the colon – the thick, viscoelastic barrier between your intestinal epithelial cells (the barrier itself) and the fecal stream.

This is a specific niche. Most gut bacteria float in the lumen – the open cavity of your intestine. Akkermansia is different. It's a mutualist: it feeds on mucin (the primary structural protein of mucus), degrading it into oligosaccharides (short sugar chains) and other metabolites that it both uses for energy and – critically – that leak back into the mucus and serve as growth substrates for other beneficial bacteria.

The bacteria itself is a gram-negative rod, strictly anaerobic (it cannot survive in oxygen), and comprises roughly 1–3% of the microbiota in healthy adults. When it declines, it usually declines steeply – from 1–3% to effectively zero.

Why It Matters: The Longevity Connection

The first hint that Akkermansia was special came in 2013.

Everard et al. published a landmark study in the Proceedings of the National Academy of Sciences (PMID 23671105) showing that genetically obese mice (ob/ob mice, lacking leptin signaling) had dramatically reduced Akkermansia compared to lean controls. More intriguingly, Akkermansia levels correlated inversely with:

• Insulin resistance – lower Akkermansia = higher fasting glucose and impaired glucose tolerance
• Systemic inflammation – measured via LPS (lipopolysaccharide) in blood, which weakly correlates with obesity-driven metabolic disease
• Body fat percentage – even controlling for total weight

The researchers proposed a mechanism: Akkermansia strengthens the gut barrier. Without it, intestinal permeability increases, allowing bacterial lipopolysaccharides (LPS – endotoxin produced by gram-negative bacteria) to translocate into the bloodstream. This drives low-grade systemic inflammation ("metabolic endotoxemia"), which impairs insulin signaling and promotes weight gain. Akkermansia, by producing anti-inflammatory signals and reinforcing the barrier, prevents this cascade.

The Centenarian Evidence

The longevity connection became explicit a few years later. Centenarian microbiome studies – particularly from Japanese populations – consistently identified Akkermansia as one of three bacterial species that distinguished the very old from the merely old.

In the Sato et al. 2021 Nature cohort of 160 Japanese centenarians (average age 107, PMID 34325466), Akkermansia was enriched compared to elderly controls (ages 85–89). The same signal appears in Italian centenarian cohorts (Biagi et al., 2016, Current Biology). This isn't correlation by accident – it appears in multiple independent populations, suggesting Akkermansia is part of a broadly protective microbial signature.

The causality remains unclear. It's possible that healthy, long-lived people naturally harbor more Akkermansia because their diet, exercise, and metabolic health support it. Or Akkermansia actively protects, and its presence is causal. The evidence below suggests both are true.

The Mechanisms: How Akkermansia Works

Akkermansia influences longevity and metabolic health through at least four distinct pathways.

1. Barrier Fortification

Akkermansia strengthens the intestinal epithelial barrier by upregulating tight junction proteins (ZO-1, occludin, claudins, JAM-3 – the molecular "glue" that seals adjacent cells together). In studies, increased Akkermansia correlates with reduced intestinal permeability, measured by lactulose/mannitol ratios in urine (a marker of leaky gut).

The mechanism is partly direct – Akkermansia's metabolites provide signaling cues to epithelial cells – and partly indirect. By fermenting mucin, Akkermansia creates an environment that favors other butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia spp.), which produce butyrate (a short-chain fatty acid, SCFA – a 4-carbon organic acid produced when gut bacteria ferment dietary fiber; functions as both fuel for colonocytes and a histone deacetylase inhibitor, altering gene expression). Butyrate is the primary fuel for intestinal epithelial cells and a potent signal for barrier integrity.

2. TLR2 Signaling and Anti-Inflammation

The most specific discovery came from Plovier et al. 2017 (Nature Medicine, PMID 27892954). The team identified a protein on the Akkermansia cell surface called Amuc_1100 (a protein component of the Akkermansia outer membrane). Amuc_1100 binds to TLR2 (Toll-like receptor 2 – a pattern recognition receptor on immune cells that detects bacterial components), triggering an anti-inflammatory response: upregulation of IL-10 (an anti-inflammatory cytokine – a signaling protein that reduces inflammation) and suppression of TNF-α and IL-6 (pro-inflammatory cytokines).

This is crucial. The immune system doesn't treat all bacteria equally. Akkermansia's specific surface proteins are recognized by innate immunity as "beneficial" – they're immunogenic (they trigger an immune response) but in a way that promotes immune tolerance rather than inflammation.

3. GLP-1 Stimulation and Metabolic Control

Akkermansia produces a protein called P9 (also referred to in some literature as outer membrane protein 35, OMP35) that activates L-cells in the intestinal epithelium – specialized neuroendocrine cells that secrete GLP-1 (glucagon-like peptide-1 – a hormone that triggers insulin secretion, slows gastric emptying, and promotes satiety).

The effect size is dramatic in vitro – up to 2,000% increase in GLP-1 secretion from isolated L-cells treated with Akkermansia supernatant. However, in vivo effects are more modest. The Depommier 2019 human trial (below) showed real but measurable benefits.

The mechanism involves ICAM-2 upregulation – Akkermansia's signals increase ICAM-2 (intercellular adhesion molecule-2) expression on L-cells, which enhances GLP-1 secretion in response to nutrient sensing.

4. Mucus Layer Regulation (The Paradox)

Here's where Akkermansia's biology gets counterintuitive: it feeds on mucin, yet its presence increases mucin production.

The research isn't fully mechanistic, but the phenomenon is real and reproducible. Akkermansia stimulates MUC2 expression (the primary structural mucin protein) in goblet cells (specialized intestinal epithelial cells that secrete mucus). The result: the mucus layer becomes thicker and more robust, even as Akkermansia grazes on it. This is stable homeostasis – Akkermansia stimulates the resource it consumes.

Without Akkermansia, the mucus layer degrades. Aging mice naturally lose Akkermansia, and supplementation partially reverses this decline, preventing the age-associated thinning of the mucus layer (Ercc1 mouse studies, PMID 30899315).

Watch: Akkermansia muciniphila and gut microbiome health for metabolic function

The Human Evidence: Depommier 2019 and Beyond

The first randomized, placebo-controlled human trial of Akkermansia came in 2019.

Depommier et al., Nature Medicine 2019 (PMID 31263284): A double-blind, placebo-controlled trial in 32 overweight/obese adults with metabolic syndrome (n=32 completers). Participants received either live Akkermansia (10^10 CFU/day – 10 billion cells), pasteurized Akkermansia (same dose), or placebo for 12 weeks.

Key findings:

• Pasteurized Akkermansia improved insulin sensitivity. Measured via HOMA-IR (homeostatic model assessment of insulin resistance – a proxy for insulin sensitivity), pasteurized Akkermansia showed significant improvement. Live Akkermansia showed a trend but didn't reach statistical significance.
• Lipid profile improved. Triglycerides and cholesterol decreased significantly with pasteurized (not live) Akkermansia.
• No adverse events. The trial was small and short (12 weeks), but no safety signals emerged.

The live vs. pasteurized finding was shocking because it contradicted industry marketing – most probiotics are sold as live cultures, with the assumption that living bacteria are necessary for colonization and efficacy. The Depommier results suggested the opposite: the immunogenic compounds on Akkermansia's surface (like Amuc_1100) were doing the work, and dead bacteria transported those compounds just as well as live ones.

This finding aligns with Plovier 2017 mouse studies, which also showed pasteurized > live.

Pendulum's Multi-Strain Trial: Perraudeau 2020 (PMID 32675291):

The only other human RCT of Akkermansia-containing probiotics tested Pendulum's "Glucose Control" blend – a 5-strain mixture (Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis, and Anaerobutyricum hallii). The trial enrolled 76 type 2 diabetics, gave them 8.5×10^9 CFU/day, and measured HbA1c (glycosylated hemoglobin, a 2–3 month average of blood glucose) and postprandial glucose (blood glucose after meals).

Results:

• HbA1c decreased 0.6% on average (control: no significant change)
• Postprandial glucose area-under-curve decreased 33% (vs control)
• Diarrhea and abdominal discomfort were reported in ~20% of treatment arm

Critical limitations:

• This is a multi-strain formulation, not Akkermansia-specific. You cannot isolate which strain drove the effect.
• Single trial, unreplicated. No independent group has reproduced it.
• n=76, only 12 weeks.
• The strain is live, contradicting the Depommier/Plovier evidence that pasteurized is superior.

The Pasteurized vs. Live Tension

This is the unresolved crux of Akkermansia supplementation.

The Science Says: Pasteurized is Better

• Plovier 2017 mouse studies clearly showed pasteurized Akkermansia was more metabolically effective than live
• Depommier 2019 human trial showed pasteurized reached significance; live did not
• The mechanism (Amuc_1100 TLR2 signaling, P9 GLP-1 triggering) doesn't require living bacteria – the proteins on the cell surface are sufficient

Industry Practice: Live Bacteria

• Pendulum uses live strain (argues that live bacteria can colonize and establish long-term residence)
• The Akkermansia Company (founded by Patrice Cani, the primary researcher) sells pasteurized Akkermansia (WB-EL21 strain) under the brand "Akkermansia Company"
• Probiotic convention favors live cultures – consumer perception associates "live" with "active"

The Resolution in Humans: Unknown No head-to-head trial has directly compared live vs. pasteurized Akkermansia in humans. The Depommier trial showed a signal for pasteurized, but it was a pilot study. Until a larger, dedicated trial tests both forms, we're extrapolating from mouse data and one human study.

This is a real gap in the evidence base. It means:

• If you take Pendulum (live), the assumption is you need colonization – sustained establishment in the gut – for long-term benefit
• If you take Akkermansia Company (pasteurized), the assumption is the cell-surface antigens are the active component
• There's no consensus on which assumption is correct

The Pendulum Probiotic: Honest Assessment

Pendulum Bioscience makes the most recognizable Akkermansia supplement in the U.S. market. Let's be specific about what we know and don't know.

The Company & Hype

Pendulum was founded by Colleen Cutcliffe, a researcher in bacterial genomics. The company raised $25+ million in venture capital and became notable after Halle Berry joined as an investor and Chief Communications Officer. Berry has type 2 diabetes (T2D) and publicly stated she uses Pendulum's products for blood glucose management.

This created a marketing halo. Halle Berry + longevity supplement = massive consumer interest.

The Product Claims

Pendulum makes four main products:

• Glucose Control – the 5-strain blend tested in Perraudeau 2020 (HbA1c -0.6%)
• Akkermansia (standalone) – pure live Akkermansia (NOT independently tested in RCT)
• Microbiome Fitness – multi-strain
• Omega+Akkermansia – Akkermansia + omega-3

Cost: ~$65–75/month for Glucose Control (the most studied), or ~$780–900/year on annual subscription.

What Works

• Real scientific pedigree. The Perraudeau trial is a legitimate RCT with measurable metabolic improvements. It's not large or replicated, but it's not a sham study.
• Reasonable dosing. 8.5×10^9 CFU/day aligns with other probiotic research ranges.
• Manufacturing standards. Pendulum publishes strain ID, CFU counts, and third-party testing – a bare minimum but important.

What Doesn't

• The standalone Akkermansia product has zero human trial data. You cannot buy Akkermansia from Pendulum with any RCT support for that specific product.
• The live/pasteurized contradiction. Pendulum's marketing emphasizes "live, potent cultures" and "colonization," but the mechanistic research suggests pasteurized is more effective. They're selling what feels right, not what the evidence supports.
• The Glucose Control RCT is multi-strain. It's impossible to know how much the HbA1c improvement was driven by Akkermansia vs. the other four strains.
• No long-term data. 12 weeks is the longest human data available. We don't know if benefits persist, worsen, or plateau over months/years.
• Price relative to natural alternatives. $780/year for a multi-strain supplement with one small trial, vs. $0/year for polyphenols and intermittent fasting with multiple human trials showing Akkermansia boosting.

Natural Ways to Boost Akkermansia (Evidence-Ranked)

If the science of Akkermansia supplementation is thin, the science of naturally boosting Akkermansia is robust. Here are the evidence-backed interventions.

1. Polyphenols (Strongest Evidence)

Polyphenols (phenolic compounds produced by plants; include flavonoids, phenolic acids, and other structures that provide bitter or astringent taste) selectively feed Akkermansia.

Anhê et al. 2015, Gut (PMID 25080446): A randomized crossover trial in 16 healthy adults. Participants consumed cranberry juice (high polyphenol) or control for 4 weeks, with a washout period, then switched. Cranberry supplementation significantly increased Akkermansia (and other polyphenol-responsive bacteria like Bifidobacterium).

Roopchand et al. 2015 (PMID 25845659): A study of grape pomace (the solid residue after grape juice extraction, rich in polyphenol) in overweight humans. Grape pomace supplementation increased Akkermansia and improved insulin sensitivity.

Mechanism: Polyphenols are poorly absorbed in the small intestine and reach the colon intact, where Akkermansia (and other bacteria) ferment them into short-chain fatty acids and other bioactive metabolites. Akkermansia is specifically adapted to polyphenol fermentation.

Practical application:

• Berries (blueberries, blackberries, raspberries) – highest polyphenol density
• Pomegranate
• Red wine (moderate consumption)
• Green/black tea
• Dark chocolate (70%+ cacao)
• Aim for ~400–600 mg/day polyphenols (equivalent to 1–2 servings of berries + 1 glass wine or green tea)

No RCT has tested whether "just eat polyphenols" boosts Akkermansia as effectively as a multi-strain probiotic + polyphenols, but the evidence suggests polyphenols alone have metabolic benefits independent of Akkermansia.

2. Metformin (High Indirect Evidence)

Metformin – the most commonly prescribed type 2 diabetes medication – dramatically alters the microbiota.

de la Cuesta-Zuluaga et al. 2017, Diabetes Care (PMID 27999002): A cross-sectional observational study of gut microbiota in metformin-treated type 2 diabetics. Metformin increased Akkermansia abundance by up to 20% of the total microbiota in some patients. The effect was robust across studies and dosing regimens (500–2,550 mg/day).

Mechanism: Metformin alters glucose metabolism and reaches the colon largely unabsorbed. This changes the fermentation substrate available to bacteria – favoring Akkermansia and butyrate producers.

Shin et al. 2014, Gut (PMID 23804561): showed that metformin's glucose-lowering effect is partly mediated by microbiome changes, including Akkermansia expansion.

This creates an interesting interaction: if you're on metformin and take an Akkermansia probiotic, you're stacking two Akkermansia-boosting interventions. The additive effect is unknown but plausible.

Practical application:

• Metformin is prescription-only, but this finding suggests: if you have prediabetes or metabolic dysfunction, metformin might be the single most effective intervention – partly because it boosts Akkermansia.
• This is not medical advice – discuss with your doctor.

3. Intermittent Fasting (Moderate Evidence)

Özkul et al. 2019 (PMID 31854308): A pilot study of Ramadan fasting (intermittent fasting for 29 days, eating only at sunset/pre-dawn) in 9 healthy adults. Akkermansia increased significantly during the fasting month and partially reverted post-Ramadan.

Mechanism: Not fully understood, but fasting shifts the microbiota toward mucin-fermenting bacteria. The mucus layer becomes more prominent as a nutrient source during carbohydrate scarcity, favoring Akkermansia.

Other fasting formats: Time-restricted eating (eating within an 8–10 hour window), 24-hour fasts, or 5:2 diets have not been specifically tested for Akkermansia, but the mechanistic logic is similar.

Practical application:

• 16:8 intermittent fasting (16 hours fasting, 8-hour eating window) or 14:10
• Even one or two fasting days per month may have Akkermansia benefits
• Combine with polyphenol-rich foods during the eating window for synergy

4. Exercise (Moderate Evidence)

Barton et al. 2018, Gut (PMID 29532321): Comparing elite rugby players to sedentary controls, athletes had 2.6× higher Akkermansia levels.

Allen et al. 2018 (PMID 29988033): A study showing that exercise-induced changes in the microbiota (including Akkermansia elevation) are reversible – stopping exercise causes Akkermansia to decline.

Mechanism: Exercise increases intestinal motility (movement of the intestines, which mixes the microbiota and nutrients), upregulates immune function (favoring beneficial bacteria), and alters secondary bile acids that selectively feed Akkermansia.

Practical application:

• Endurance exercise (running, cycling, rowing) shows stronger effects than resistance training alone
• 150+ minutes/week moderate intensity or 75+ minutes/week high intensity
• Even modest exercise (brisk walking 30 min/day) likely has benefits

5. Pomegranate & Urolithin A (Emerging)

Pomegranate contains ellagic acid, which gut bacteria metabolize into urolithin A (also called urolithin; a compound that triggers mitophagy – selective autophagy of dysfunctional mitochondria – a hallmark of longevity interventions).

Early data suggests urolithin-A-producing bacteria (including Akkermansia) expand under pomegranate supplementation, though causality isn't established.

Practical application:

• Pomegranate juice or whole fruit (no commercial urolithin-A supplement has strong evidence yet)
• Combine with polyphenol-rich foods above

Safety & Limitations: The MS Concern

Akkermansia is not universally beneficial. There are contexts where elevated Akkermansia correlates with worse outcomes.

Multiple Sclerosis (MS) and Autoimmune Disease

The most specific concern comes from MS research.

Multiple lines of evidence suggest Akkermansia may worsen autoimmune disease in certain contexts:

1. CSF antibodies: MS patients show elevated Akkermansia-specific IgG in cerebrospinal fluid (the fluid surrounding the brain and spinal cord), suggesting the immune system is reacting to Akkermansia antigens in the CNS. This is not definitive proof of pathogenic causality, but it's a concerning signal.
2. EAE worsening: In experimental autoimmune encephalomyelitis (EAE – a mouse model of MS), Akkermansia supplementation worsens disease in certain microbiome contexts – specifically, in mice with dysbiosis characterized by elevated Clostridia. In healthier microbiome contexts, Akkermansia may be protective or neutral.
3. Th17 expansion: Akkermansia may expand Th17 cells (T helper 17 cells – a T cell subset involved in autoimmune responses) in specific dysbiotic states. This is context-dependent: in a healthy microbiota, Akkermansia's TLR2 signaling is anti-inflammatory. In dysbiosis, it can be pro-inflammatory.

Bottom line: If you have MS or another T-cell mediated autoimmune disease, Akkermansia supplementation is not clearly safe. Natural boosting (polyphenols, exercise) might be less risky than high-dose supplementation, but the data are sparse. Consult your neurologist before supplementing.

Cancer Immunotherapy Non-Linearity

A paradoxical finding in cancer immunotherapy: very high Akkermansia (>4.66% of the microbiota) correlates with worse outcomes in patients receiving checkpoint inhibitors (immunotherapy drugs like anti-PD-1). Moderate levels appear optimal.

This is a small, specific population, but it suggests there's an "optimal" Akkermansia level rather than "more is always better."

Post-Antibiotic Context

In mouse models, Akkermansia supplementation after antibiotic treatment can worsen colitis-associated colorectal cancer in specific contexts (PMC9614165). This is preclinical only, but suggests caution with post-antibiotic supplementation in people with colitis or CRC risk.

What This Means

• If you have MS or autoimmune disease: Avoid high-dose Akkermansia supplementation. Natural boosting (diet, exercise, fasting) might be safer.
• If you're undergoing cancer immunotherapy: Consult your oncologist before adding any probiotic or Akkermansia supplement.
• For general population: The safety signal is modest, and Akkermansia appears beneficial for metabolic health and longevity in most people. But "more" is not universally "better."

The Live vs. Pasteurized Question: Unresolved in Humans

I want to revisit this because it's the crux of product choice.

If research says pasteurized is better, why do companies sell live?

1. Regulatory precedent: Probiotics are regulated as "live microorganisms with beneficial effects." Historically, efficacy was assumed to correlate with viability. Pasteurized products blur this regulatory category.
2. Consumer psychology: People expect probiotics to be "alive." Marketing dead bacteria feels like selling an inactive supplement, even if the mechanism is valid.
3. Colonization theory: The hypothesis that live bacteria can establish permanent residence in the gut, providing ongoing benefit, has intuitive appeal. If true, live > pasteurized. But in humans, most probiotic bacteria are transient – they're shed within 2–4 weeks of stopping supplementation.
4. Conflict of interest: Patrice Cani (the primary Akkermansia researcher and director of research at the Akkermansia Company) has published the evidence for pasteurized. But he also founded/works for the company selling pasteurized Akkermansia. This creates an incentive to emphasize pasteurization's advantages.

The pragmatic answer:

• If you're going to supplement, pasteurized Akkermansia Company or equivalent has stronger mechanistic support
• If you use Pendulum (live), don't assume you're getting something "more active" – you're making a bet that live colonization matters, which isn't proven in humans
• Neither form has long-term safety data >12 weeks in humans

Expert Perspectives

Tim Spector (ZOE, King's College London)

Spector, a epidemiologist and co-founder of ZOE (a microbiome company), is skeptical of single-species probiotic claims. His position: diversity matters more than any individual species. His research shows that people eating 30+ plant species per week have dramatically higher microbiota diversity – a stronger longevity signal than any single bacterial species.

On Akkermansia supplementation, Spector's view is pragmatic: "If you're going to spend money, spend it on polyphenol-rich food first. Then exercise. Then microbiome testing to understand your actual deficiencies. Single-species probiotics are less likely to move the needle than dietary change."

Patrice Cani (Catholic University of Louvain)

Cani is the primary researcher behind Akkermansia's mechanisms (Plovier 2017, Depommier 2019, multiple other key studies). He's also founder/advisor to the Akkermansia Company, creating a conflict of interest.

His scientific position (which is strong) is that Akkermansia is a "next-generation probiotic" – not because it colonizes permanently, but because its surface antigens provide specific immune signaling (Amuc_1100 TLR2) that improves metabolic health. He advocates for pasteurized form.

On supplementation: Cani is cautious. He emphasizes that Akkermansia supplementation is an emerging intervention with limited human data, that natural boosting is preferable, and that people with autoimmune disease should be cautious.

Bryan Johnson (Blueprint Protocol)

Johnson is a longevity biohacker with significant media presence. His position on Akkermansia: he does NOT specifically supplement with Akkermansia. His microbiome protocol emphasizes polyphenol-rich foods, intermittent fasting, and fermented foods – all things that naturally boost Akkermansia without supplementation.

When asked about Pendulum, Johnson has said the supplement has "real science behind it" but that his protocol achieves similar results through diet and fasting alone.

Eran Segal (Weizmann Institute)

Segal's research on personalized nutrition shows that individuals respond highly variably to the same interventions. A probiotic that boosts Akkermansia and improves glucose control in one person might have minimal effect in another, due to differences in baseline microbiota composition, genetics, and diet.

His perspective: "Don't assume a probiotic works for you because it worked in a trial. The individual variation is enormous. Test yourself – measure Akkermansia before and after supplementation."

Testing Your Akkermansia Levels

If you're considering supplementation, it makes sense to know your baseline.

Consumer Microbiome Tests

ZOE ($300–400)

• Uses shotgun metagenomics (sequences all DNA in a stool sample, not just 16S rRNA)
• Most comprehensive and technically rigorous
• Provides Akkermansia abundance + hundreds of other species
• Longest turnaround time (~4 weeks)
• Based in UK/US

Viome ($150–250)

• Uses metatranscriptomics (sequences RNA, which reflects what bacteria are actively expressing)
• Strong focus on functional potential (what metabolites are being made), less on simple abundance counts
• Good for understanding metabolic function, weaker for absolute Akkermansia quantification
• Turnaround time ~2 weeks

Ombre/Thryve (~$100)

• Uses 16S rRNA sequencing (cheaper, less comprehensive)
• Provides Akkermansia abundance with lower resolution on other species
• Quick turnaround
• Less technically rigorous than shotgun; 16S biases can affect rare species quantification

uBiome — DEFUNCT (shut down 2019 due to regulatory issues; avoid)

Interpretation

• Akkermansia >1–2% of microbiota: Typical healthy adult range. If you have metabolic disease, you might be on the lower end (0.1–0.5%).
• <0.1%: Markedly depleted; supplementation or aggressive natural boosting might be worth trying.
• >5%: Unusually high; additional supplementation is probably not necessary.

Caveats

16S vs. shotgun sequencing can produce 2–5× differences in abundance estimates for the same sample. If you test with Ombre first and find low Akkermansia, repeating with ZOE might show different numbers. This is a technical artifact, not a change in your biology.

Who Actually Benefits? Practical Recommendations

Best Candidates for Akkermansia Supplementation (or Natural Boosting)

1. Type 2 diabetes, especially if already on metformin
   • Akkermansia is directly related to insulin sensitivity
   • Depommier 2019 showed the clearest benefit in this population
   • Adding natural boosters (polyphenols, fasting) is complementary
2. Prediabetes with documented low Akkermansia
   • Test first; if <0.5%, interventions are more likely to help
   • Natural boosting is first-line; supplement is optional
3. Metabolically obese with visceral fat and insulin resistance
   • Even if BMI is normal, elevated visceral fat + poor insulin sensitivity = benefit signal
   • Same approach: test, boost naturally first
4. Recent antibiotic course + documented low Akkermansia
   • Post-antibiotic dysbiosis is a legitimate reason to supplement
   • Polyphenols + time usually restore it; supplementation may accelerate
5. Centenarian-track biohacker optimizing every marker
   • If you're already dialed on diet, exercise, and sleep, targeting Akkermansia is a marginal gain
   • Still, natural boosting is cheaper and better-supported than supplementation

Not Good Candidates

• MS or T-cell autoimmune disease: Avoid supplementation; consult neurologist
• Very high Akkermansia (>4%): Already optimized; supplementation won't help and might backfire
• Cancer immunotherapy patient: Consult oncologist first
• Healthy metabolic markers, not on metformin, normal weight: Polyphenol-rich diet already supports Akkermansia; supplementation unnecessary

Practical Protocol (If You Decide to Supplement)

Step 1: Test (optional but smart)

• Use ZOE or Viome to establish baseline Akkermansia

Step 2: Natural Boosting First (do this for 8–12 weeks)

• Polyphenols: 1–2 servings berries/day + 1 cup green tea + 70%+ dark chocolate
• Exercise: 150 min/week moderate intensity (walking, cycling)
• Intermittent fasting: 14:10 or 16:8 if appropriate for your context
• Fiber diversity: 30+ plant species per week

Step 3: Assess

• If Akkermansia rose to 1–3% range and metabolic markers improved, stop here
• If still <0.5% after 12 weeks, consider supplementation

Step 4: If Supplementing

• Pendulum Glucose Control: $65–75/month, multi-strain, supported by one RCT (HbA1c -0.6% in T2D)
• Akkermansia Company: pasteurized, aligns with mechanistic evidence, less consumer data
• Duration: 12 weeks minimum to assess benefits
• Retest after 12 weeks to confirm Akkermansia increased

Step 5: Sustainability

• Probiotics are not "set and forget" – stopping supplementation causes levels to decline
• If you supplement, plan to continue or shift to sustained natural boosting
• Budget: $780/year supplementation vs. $0/year if using diet + exercise

FAQ

Q: Is Akkermansia the "longevity bacterium" – is it as important as people say?

A: It's one of the three most consistently longevity-associated bacteria (alongside Faecalibacterium prausnitzii and Christensenella minuta), but it's not sufficient on its own. Centenarians have a microbial ecosystem that includes Akkermansia; boosting Akkermansia alone in the context of a dysbiotic gut probably helps less than improving overall diversity. That said, in specific populations (T2D, insulin resistance, obesity), Akkermansia appears to be a particularly important lever.

Q: Should I buy Pendulum or The Akkermansia Company?

A: Neither has overwhelming evidence. If forced to choose: Akkermansia Company is more aligned with the mechanistic research (pasteurized > live). But the Perraudeau trial of Pendulum's multi-strain blend showed real benefits (-0.6% HbA1c). The honest answer: try natural boosting first (polyphenols, exercise, fasting); if metabolic markers don't improve and Akkermansia stays low, then choose based on your philosophy (Pendulum = colonization hypothesis; Akkermansia Company = immunogenic antigens hypothesis).

Q: Can I boost Akkermansia to "centenarian levels"?

A: Probably not to the exact levels of a Japanese centenarian eating a traditional diet in a longevity zone. But you can move from "low" (0.1–0.5%) to "typical healthy" (1–3%) relatively easily. The marginal returns diminish after ~2–3%.

Q: Does Akkermansia supplementation interact with other supplements?

A: Limited data. In theory, polyphenols + Akkermansia might be synergistic (polyphenols feed the bacteria). Metformin + Akkermansia likely stacks additive effects on glucose control. Avoid with antibiotics (obviate). No data on interactions with berberine, NAD+ precursors, or other longevity compounds, but no theoretical conflicts.

Q: How long does it take to see benefits?

A: Depommier 2019 showed improvements in 12 weeks (HbA1c takes 2–3 months to fully reflect blood glucose changes). Glucose and lipids might shift faster (4–8 weeks). Don't expect overnight changes.

Q: Is Akkermansia supplementation safe long-term?

A: No long-term data >12 weeks exists in humans. Short-term data (12 weeks) is reassuring – no severe adverse events. But "safe for 1 year or 5 years of continuous supplementation" is not established. The microbiota is complex; long-term effects of any single-species supplementation are incompletely understood.

Q: Can I take Akkermansia if I have autoimmune disease?

A: Probably not advisable for MS or T-cell mediated autoimmunity. Consult your rheumatologist or neurologist. Natural boosting might be safer, but no data exist.

Q: Does Akkermansia help with weight loss directly?

A: Not without metabolic improvement. Akkermansia improves insulin sensitivity and gut barrier function – if these changes support weight loss via better appetite regulation and reduced inflammation, yes. But the direct mechanism isn't "Akkermansia eats calories." It's an indirect effect on metabolic health.

The Real Picture

The science of Akkermansia muciniphila is genuinely interesting. It's one of the few bacteria where mechanistic research (Amuc_1100, TLR2 signaling, GLP-1 P9 protein) is specific enough to make testable predictions. And the predictions hold up: Akkermansia does appear to improve insulin sensitivity, strengthen the gut barrier, and correlate with longevity in centenarians.

But between the science and a $780/year supplement, there's a gap.

The human evidence is thin: one 12-week trial in 32 people (Depommier, pasteurized form) and one multi-strain trial in 76 people with T2D (Perraudeau, live form). Neither is a slam dunk. The live vs. pasteurized question remains unresolved in humans. The long-term safety is unknown. And the natural alternatives (polyphenols, metformin, exercise, fasting) have stronger evidence bases for Akkermansia boosting.

Bottom line:

• If you have type 2 diabetes and low Akkermansia, supplementation (Pendulum or equivalent) is worth trying after 12 weeks of natural boosting.
• If you're metabolically healthy but curious, skip the supplement and eat more berries, green tea, exercise, and fast intermittently.
• If you have autoimmune disease, avoid Akkermansia supplementation pending more data.
• Testing your actual Akkermansia level before spending money is smart.
• Bryan Johnson was right: diet and fasting naturally support Akkermansia without the price tag.

Related Reading

Gut Microbiome and Longevity: What Your Bacteria Have to Do With Aging (2026)

Metformin and Longevity: Beyond Blood Sugar (2026)

Berberine: The Herbal Metformin Alternative (2026)

Urolithin A and Mitophagy: The Pomegranate Longevity Connection (2026)

Intermittent Fasting and Longevity: What the Research Actually Shows (2026)

GLP-1, Ozempic, and Longevity: What You Need to Know (2026)

NAD+ and Gut Health: Why Your Microbiome Matters for Cellular Energy (2026)

Fasting and Supplements: What Breaks Your Fast (2026)

Daily Compounds — your habits are dialed. Your cells aren't. Learn more →